나노에멀전 시장 : 유형별, 투여 경로별, 용도별, 지역별(2025-2033년)

The global nanoemulsion market size reached USD 12.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 23.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The market is flourished by the increasing consumer awareness about nutraceuticals, rising demand for advanced drug delivery systems, ongoing research and development (R&D) activities in nanotechnology, and expanding product applications in the food and beverage industry.

Nanoemulsions are thermodynamically stable isotropic systems wherein two immiscible liquids are mixed using an emulsifying agent like surfactant and co-surfactant. They are safe, effective, non-toxic, and non-irritant and have small-sized droplets with a greater surface area that provide better absorption and improved physical stability. As a result, they are used as carriers of drug molecules in pharmaceutical systems to improve the delivery of active pharma ingredients. They also help protect drugs that are susceptible to hydrolysis and oxidation, enable prolonged action of the medicaments, and provide better uptake of oil-soluble supplements in cell culture technology.

Nanoemulsion Market Trends:

The rising prevalence of chronic diseases, along with increasing preferences for smart and precision drug delivery systems, represents one of the key factors catalyzing the demand for nanoemulsions worldwide. Moreover, nanoemulsions are used for targeted drug delivery of various anticancer drugs, photosensitizers, and therapeutic agents. In addition, as they can enhance the therapeutic efficacy of drugs and minimize adverse effects and toxic reactions, they are gaining traction over conventional drug delivery systems across the globe. Apart from this, the growing aging population, which is more susceptible to critical health disorders, is propelling the need for nanoemulsions to treat reticuloendothelial system (RES) infection and in the enzyme replacement therapy of the liver. Besides this, they are employed in the cosmetics and personal care industries to manufacture foams, creams, liquids, and sprays. Furthermore, increasing demand for functional food on account of the rising health consciousness among individuals is positively influencing the applications of nanoemulsions in the food and beverage (F&B) industry. They assist in improving the digestibility of food and the bioavailability of active components.

Key Market Segmentation:

Breakup by Type:

• Small-molecule Surfactant
• Protein-stabilized Emulsions
• Polysaccharide

Breakup by Route of Administration:

• Oral
• Parenteral
• Others

Breakup by Application:

• Anesthetics
• Antibiotics
• Nonsteroidal Anti-inflammatory Drugs
• Immunosuppressants
• Steroids
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ascendia Pharmaceuticals, B. Braun Melsungen AG, BlueWillow Biologics Inc., Covaris Inc., Fresenius Kabi AG, IDEX Corporation, Kaken Pharmaceutical Co. Ltd., Latitude Pharmaceuticals Inc., Owen Biosciences Inc., Santen Pharmaceutical Co. Ltd and Taiwan Liposome Co. Ltd.

Key Questions Answered in This Report

• 1.What was the size of the global nanoemulsion market in 2024?
• 2.What is the expected growth rate of the global nanoemulsion market during 2025-2033?
• 3.What are the key factors driving the global nanoemulsion market?
• 4.What has been the impact of COVID-19 on the global nanoemulsion market?
• 5.What is the breakup of the global nanoemulsion market based on the type?
• 6.What is the breakup of the global nanoemulsion market based on the application?
• 7.What are the key regions in the global nanoemulsion market?
• 8.Who are the key players/companies in the global nanoemulsion market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Nanoemulsion Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Small-molecule Surfactant
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Protein-stabilized Emulsions
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Polysaccharide
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Parenteral
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Anesthetics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Antibiotics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Nonsteroidal Anti-inflammatory Drugs
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Immunosuppressants
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Steroids
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Other
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Ascendia Pharmaceuticals
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 B. Braun Melsungen AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 BlueWillow Biologics Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Covaris Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Fresenius Kabi AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 IDEX Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Kaken Pharmaceutical Co. Ltd.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Latitude Pharmaceuticals Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Owen Biosciences Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Santen Pharmaceutical Co. Ltd
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Taiwan Liposome Co. Ltd.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio